Skip to main content
SpringerLink
Log in

Screening for cystic fibrosis: the practice and the debate

  • Article
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Cystic fibrosis is a serious disorder that has been defined on the basis of clinical description, physiological abnormality and more recently by DNA based testing. Newborn screening based upon measurement of immunoreactive trypsin with follow up by DNA testing is capable of detecting cases very often without the need of a sweat test and with the requirement for a second sample reduced to only 1 in 4,200 of those tested. While this efficient system avoids substantial parental anxiety, it does reveal a significant number of heterozygous parents who will require genetic counselling. There is some preliminary evidence for improved growth in the screened population; however, the main benefits of screening result from the improved efficiency of the healthcare system and reduction in the length of time required to make a diagnosis. The arguments relating to screening for cystic fibrosis are more finely balanced than those of previous programmes such as phenylketonuria screening and the benefits of early intervention are less obvious. In addition, the potential harmful effects of unwanted genetic information are more apparent. Conclusion:on this basis while the case for screening appears justified the need to ensure properly informed consent appears even more pressing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IRT :

immunoreactive trypsin

References

  1. Anderson DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56: 334

    Google Scholar 

  2. Chatfield S, Owen G, Ryley HC, Williams J, Goodchild MC, Weller P (1991) Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child 66: 29–33

    CAS  PubMed  Google Scholar 

  3. Crossley JR, Elliot RB, Smith PA (1979) Dried blood spot screening for cystic fibrosis in the newborn. Lancet 1: 472–474

    Article  CAS  PubMed  Google Scholar 

  4. Di Santi’Agnese PA, Darling RC, Perera GA, Shea A (1953) Abnormal composition of sweat in cystic fibrosis of the pancreas: clinical significance and relationship to the disease. Pediatrics 12: 549–563

    PubMed  Google Scholar 

  5. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Hoffman G et al (1998) Assessment of the benefits, risks and costs of cystic fibrosis screening in Wisconsin, USA. Proceedings of the Fifth International Conference on Neonatal Screening for Cystic Fibrosis, pp 239–253.

  6. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, Splaingard ML (2001) Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 107: 1–13

    PubMed  Google Scholar 

  7. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A et al (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073–1080

    CAS  PubMed  Google Scholar 

  8. Merelle ME, Lees CM, Nagelkerke AF, Dezateux C (2001) Newborn screening in cystic fibrosis. Cochrane Database System Rev 2: CD001402.

    Google Scholar 

  9. Rostenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Consensus Panel. J Pediatr 132: 589–595

    CAS  PubMed  Google Scholar 

  10. Seybold P (2001) The customer revolution. Random House Business Books, London

  11. Stephan U, Busch EW, Kollberg H, Hellsing K (1975) Cystic fibrosis testing by means of a test strip. Pediatrics 55: 35–38

    CAS  PubMed  Google Scholar 

  12. Waters DL, Wilcken B, Irwing L, Van Asperen P, Mellis C, Simpson JJ, Gaskin KJ (1999) Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 80: F1–F7

    CAS  PubMed  Google Scholar 

  13. Widdicombe JH, Welsh MJ, Finkbeiner WE (1985) Cystic fibrosis decreases the apical membrane chloride permeability of monolayers cultured from cells of tracheal epithelium. Proc Natl Acad Sci USA 82: 6167–6171

    CAS  PubMed  Google Scholar 

  14. Wilson JMG, Junger G (1968) Principals and practice of screening for disease. Bol Oficina Sanit Panam 65: 281–293

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Chemistry and Newborn Screening, Sheffield Children’s (NHS) Trust, S10 2TH, Sheffield, UK

    James R. Bonham & Melanie Downing

  2. Department of Molecular Genetics, Sheffield Children’s (NHS) Trust, S10 2TH, Sheffield, UK

    Ann Dalton

Authors
  1. James R. Bonham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melanie Downing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ann Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James R. Bonham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonham, J.R., Downing, M. & Dalton, A. Screening for cystic fibrosis: the practice and the debate. Eur J Pediatr 162 (Suppl 1), S42–S45 (2003). https://doi.org/10.1007/s00431-003-1350-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-003-1350-4

Keywords

Search

Navigation